» Articles » PMID: 21076956

External Validation of the UK Prospective Diabetes Study (UKPDS) Risk Engine in Patients with Type 2 Diabetes

Overview
Journal Diabetologia
Specialty Endocrinology
Date 2010 Nov 16
PMID 21076956
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Aims/hypothesis: Treatment guidelines recommend the UK Prospective Diabetes Study (UKPDS) risk engine for predicting cardiovascular risk in patients with type 2 diabetes, although validation studies showed moderate performance. The methods used in these validation studies were diverse, however, and sometimes insufficient. Hence, we assessed the discrimination and calibration of the UKPDS risk engine to predict 4, 5, 6 and 8 year cardiovascular risk in patients with type 2 diabetes.

Methods: The cohort included 1,622 patients with type 2 diabetes. During a mean follow-up of 8 years, patients were followed for incidence of CHD and cardiovascular disease (CVD). Discrimination and calibration were assessed for 4, 5, 6 and 8 year risk. Discrimination was examined using the c-statistic and calibration by visually inspecting calibration plots and calculating the Hosmer-Lemeshow χ(2) statistic.

Results: The UKPDS risk engine showed moderate to poor discrimination for both CHD and CVD (c-statistic of 0.66 for both 5 year CHD and CVD risks), and an overestimation of the risk (224% and 112%). The calibration of the UKPDS risk engine was slightly better for patients with type 2 diabetes who had been diagnosed with diabetes more than 10 years ago compared with patients diagnosed more recently, particularly for 4 and 5 year predicted CVD and CHD risks. Discrimination for these periods was still moderate to poor.

Conclusions/interpretation: We observed that the UKPDS risk engine overestimates CHD and CVD risk. The discriminative ability of this model is moderate, irrespective of various subgroup analyses. To enhance the prediction of CVD in patients with type 2 diabetes, this model should be updated.

Citing Articles

Precision prognostics for cardiovascular disease in Type 2 diabetes: a systematic review and meta-analysis.

Ahmad A, Lim L, Morieri M, Tam C, Cheng F, Chikowore T Commun Med (Lond). 2024; 4(1):11.

PMID: 38253823 PMC: 10803333. DOI: 10.1038/s43856-023-00429-z.


External validation of the UK prospective diabetes study (UKPDS) risk engine in patients with type 2 diabetes identified in the national diabetes program in Iran.

Valipour M, Khalili D, Solaymani-Dodaran M, Motevalian S, Khamseh M, Baradaran H J Diabetes Metab Disord. 2023; 22(2):1145-1150.

PMID: 37975087 PMC: 10638115. DOI: 10.1007/s40200-023-01224-2.


First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.

Choi J, Winn A, Skandari M, Franco M, Staab E, Alexander J Ann Intern Med. 2022; 175(10):1392-1400.

PMID: 36191315 PMC: 10155215. DOI: 10.7326/M21-2941.


The Korean Hypertension Cohort study: design and baseline characteristics.

Lee H, Lee J, Shin H, Cho S, Park K, Oh G Korean J Intern Med. 2021; 36(5):1115-1125.

PMID: 34289586 PMC: 8435490. DOI: 10.3904/kjim.2020.551.


Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials.

Rao L, Ren C, Luo S, Huang C, Li X Acta Diabetol. 2021; 58(7):869-880.

PMID: 33651228 PMC: 8187227. DOI: 10.1007/s00592-021-01686-x.


References
1.
Pencina M, DAgostino Sr R, Larson M, Massaro J, Vasan R . Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation. 2009; 119(24):3078-84. PMC: 2748236. DOI: 10.1161/CIRCULATIONAHA.108.816694. View

2.
Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson P, Gudbjornsdottir S . Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diabetes Care. 2008; 31(10):2038-43. PMC: 2551651. DOI: 10.2337/dc08-0662. View

3.
Boeing H, Korfmann A, Bergmann M . Recruitment procedures of EPIC-Germany. European Investigation into Cancer and Nutrition. Ann Nutr Metab. 1999; 43(4):205-15. DOI: 10.1159/000012787. View

4.
Guzder R, Gatling W, Mullee M, Mehta R, Byrne C . Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study. Diabet Med. 2005; 22(5):554-62. DOI: 10.1111/j.1464-5491.2005.01494.x. View

5.
Stephens J, Ambler G, Vallance P, Betteridge D, Humphries S, Hurel S . Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory?. Eur J Cardiovasc Prev Rehabil. 2004; 11(6):521-8. DOI: 10.1097/01.hjr.0000136418.47640.bc. View